WST — West Pharmaceutical Services, I
Is WST overbought or oversold? Here is the current MarketMoodz read.
West Pharmaceutical Services, I (WST) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $414.12. The rating moved from Neutral to Overbought on November 12, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$414.12
- Last changeMoved from Neutral to Overbought on November 12, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all overbought Healthcare stocks →
AI analysis
West Pharmaceutical Services, I (WST) is well positioned as a supplier of primary packaging and delivery components to the growing injectable and biologics market. Its durable consumables revenue mix and scale provide relatively predictable cash flow while sector dynamics (increased adoption of chronic injectables and specialty pharmacy flows) create a favorable demand backdrop. Key near‑term drivers include volume growth from new chronic injectables and the company’s ability to execute on capacity expansion, while primary risks center on customer concentration, regulatory/quality events, and supply‑chain constraints. Market sentiment is neutral-to-cautious with consolidation characteristics; absent a material industry shock, the company is likely to see moderate upside from current levels over the coming month assuming steady execution.
Key factors
- Market leadership in injectable containment, elastomer components and drug delivery systems with strong customer relationships across large pharma and biotech
- Secular growth in injectable and biologic therapeutics (including GLP-1/amylin class) supports sustained demand for primary packaging and delivery components
- Recurring consumables revenue model (replacement stoppers/inserts and components) provides predictable cash flow and margin resilience
- Favorable sector flows into defensive large‑cap pharma/healthcare suppliers during consolidation market tone
- Potential upside from distributor/specialty channel expansion as chronic injectable therapies broaden patient populations
- Operational scale and manufacturing footprint that can capture incremental share as drug volumes grow
Risks
- Customer concentration risk: reliance on a limited number of large pharma/biotech customers could depress volumes/pricing if one reduces orders
- Regulatory and quality risk: recall, manufacturing hold or regulatory action on components would have outsized revenue impact
- Supply‑chain and capacity constraints: disruptions or inability to scale capacity to meet accelerated injectable demand could impair growth
- Pricing pressure and margin compression from competition or contract renegotiations
- Macroeconomic or healthcare policy changes that reduce drug pricing or slow pharma capex could indirectly limit order growth
- FX exposure and commodity cost volatility that could pressure operating margins
- Slower-than-expected adoption of new injectable therapies or changes in treatment patterns that reduce volume growth
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for WST — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.